# Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

> **NCT02955758** · PHASE2 · COMPLETED · sponsor: **Joel Neal** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02955758
- **Lead sponsor:** Joel Neal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955758, "Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02955758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*